Case Report
The need for a holistic guide to prevent and manage radiation dermatitis in patients’ with breast cancer: a case report
Translational Breast Cancer Research
2024;
5:
17
(30 April 2024)
Editorial Commentary
New role for GCH1 in cancer
Translational Breast Cancer Research
2024;
5:
16
(30 April 2024)
Editorial Commentary
Metabolomics combined with mathematical analysis reveals metabolic pathways specific to metastatic cancers
Translational Breast Cancer Research
2024;
5:
15
(30 April 2024)
Review Article
Breast fat grafting and cancer: a systematic review of the science behind enhancements and concerns
Translational Breast Cancer Research
2024;
5:
14
(30 April 2024)
Review Article
Breast surgery after neoadjuvant systemic therapy
Translational Breast Cancer Research
2024;
5:
13
(30 April 2024)
Review Article
Evolution of localization methods for non-palpable breast lesions: a literature review from a translational medicine perspective
Translational Breast Cancer Research
2024;
5:
12
(30 April 2024)
Review Article
Internal mammary lymphadenopathy in breast cancer: a narrative review and update
Translational Breast Cancer Research
2024;
5:
11
(30 April 2024)
Review Article
Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer
Translational Breast Cancer Research
2024;
5:
10
(30 April 2024)
Expert Consensus
Expert consensus on the clinical application of immunotherapy in breast cancer: 2024
Translational Breast Cancer Research
2024;
5:
9
(30 April 2024)
Case Report
A case report of low-dose apatinib in the treatment of advanced triple-negative breast cancer
Translational Breast Cancer Research
2024;
5:
8
(31 January 2024)
Case Report
Poland syndrome combined with breast cancer: a case report
Translational Breast Cancer Research
2024;
5:
7
(31 January 2024)
Brief Report
Can Hounsfield units on chest CT characterize breast nodules as cystic or solid?
Translational Breast Cancer Research
2024;
5:
6
(31 January 2024)
Editorial Commentary
Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer
Translational Breast Cancer Research
2024;
5:
5
(31 January 2024)
Review Article
Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives
Translational Breast Cancer Research
2024;
5:
4
(31 January 2024)
Review Article
Challenges in HER2-low breast cancer identification, detection, and treatment
Translational Breast Cancer Research
2024;
5:
3
(31 January 2024)
Review Article
Narrative review on advancing breast cancer treatment: harnessing the power of PD-1/PD-L1 inhibitors for improved patient outcomes
Translational Breast Cancer Research
2024;
5:
2
(31 January 2024)
Review Article
TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer
Translational Breast Cancer Research
2024;
5:
1
(31 January 2024)
Case Report
CDK4/6 inhibitors for primary endocrine resistant HR-positive/HER2-negative metastatic breast cancer: a case report
Translational Breast Cancer Research
2023;
4:
33
(31 October 2023)
Editorial
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
Translational Breast Cancer Research
2023;
4:
32
(31 October 2023)
Editorial
Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
Translational Breast Cancer Research
2023;
4:
31
(31 October 2023)
Review Article
Androgen receptor in breast cancer and its clinical implication
Translational Breast Cancer Research
2023;
4:
30
(31 October 2023)
Review Article
A clinical perspective on oncoplastic breast conserving surgery
Translational Breast Cancer Research
2023;
4:
29
(31 October 2023)
Review Article
New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment
Translational Breast Cancer Research
2023;
4:
28
(31 October 2023)
Original Article
Self-detection remains a primary means of breast cancer detection in Beijing, China
Translational Breast Cancer Research
2023;
4:
27
(31 October 2023)
Original Article
Interaction of de novo cholesterol biosynthesis and Hippo signaling pathway in ductal carcinoma in situ (DCIS)—comparison with the corresponding normal breast epithelium
Translational Breast Cancer Research
2023;
4:
26
(31 October 2023)